Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Comment by lovingoldon Dec 15, 2022 1:53am
122 Views
Post# 35172431

RE:RE:RE:Everyone needs to relax!

RE:RE:RE:Everyone needs to relax!Did xB3 fail, zwerp2000? Is that the program failure? The answer is pretty obvious. XB3 failed.

Absolutely, 
unequivocally, not a truthful statement. It's actually humourus what a blatant lie it is.
Ask them in a public forum such as the webinar on Tuesday, or any Board member like Mario Saltarelli or Mei Mei (head scientist) if xB3 has failed in any study that Bioasis or any of their partners has done over the years ==> the answer is NO.

Is it possible for xB3 to sucessfully transport a (the pharma's) drug across the BBB (Blood-brain barrier) and then the drug doesn't work (as intended)? Yes, but that is the pharmas issue with their drug not a problem with xB3. Although it is in a sense our problem in that they won't sign a huge licensing deal if their drug doesn't work (effectively) once it gets across the BBB.
<< Previous
Bullboard Posts
Next >>